Squarepoint’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Squarepoint’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-113,437	Closed	-$527K	–	3852
2021 Q1	$527K	Buy	113,437 +52,219	+85%	+$237K	﹤0.01%	1974
2020 Q4	$202K	Sell	61,218 -1,427	-2%	-$5.42K	﹤0.01%	2512
2020 Q3	$207K	Sell	62,645 -82,115	-57%	-$302K	﹤0.01%	2070
2020 Q2	$488K	Buy	+144,760	New	+$685K	0.01%	1333
2020 Q1	–	Sell	-17,254	Closed	-$104K	–	2693
2019 Q4	$104K	Buy	17,254 +5,345	+45%	+$36.6K	﹤0.01%	2339
2019 Q3	$90K	Buy	+11,909	New	+$134K	﹤0.01%	2203
2019 Q2	–	Sell	-24,453	Closed	-$133K	–	2747
2019 Q1	$133K	Buy	+24,453	New	+$119K	﹤0.01%	2007
2018 Q4	–	Sell	-14,861	Closed	-$121K	–	2320
2018 Q3	$121K	Buy	14,861 +1,119	+8%	+$8.59K	﹤0.01%	1859
2018 Q2	$134K	Buy	+13,742	New	+$141K	﹤0.01%	1609
2018 Q1	–	Sell	-19,843	Closed	-$248K	–	2269
2017 Q4	$248K	Buy	+19,843	New	+$227K	﹤0.01%	1650

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's ZYNE Position: Q2 2021 in Review

Squarepoint sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2021, closing a stake of 113,437 shares — an estimated $527K sold.

Squarepoint first reported a position in ZYNE in Q4 2017 and held it in 10 quarters. The position peaked at $527K in Q1 2021. 65 funds tracked by Wall St. Rank hold ZYNE as of Q2 2021.

Squarepoint reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 113,437 Zynerba Pharmaceuticals, Inc shares in Q2 2021, an estimated $527K.
Squarepoint first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 10 quarters.
Squarepoint's Zynerba Pharmaceuticals, Inc position peaked at $527K in Q1 2021.
65 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.